A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

NCT ID: NCT05268666

Last Updated: 2023-06-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 126 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-08
• Study Completion Date: 2025-08-31

Brief Summary

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.

Detailed Description

This is a multi-center, first in human, open-label, 2-part, dose escalation and expansion study to define safety, tolerability, maximum tolerated dose, pharmacologically active dose, assess preliminary efficacy, and explore predictive and pharmacodynamic biomarkers in up to 126 participants with advanced solid tumors. Expansion cohorts of participants, treated at the RP2D, with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and other neuroendocrine-derived cancers will be enrolled to obtain additional safety and efficacy data. Starting dose will be 10 mg orally once daily, 4 days on and 3 days off cycle.

Conditions

Locally Advanced Solid Tumor; Metastatic Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

JBI-802

10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle

Group Type: EXPERIMENTAL

JBI-802

Intervention Type: DRUG

LSD1/HDAC6 inhibitor

Interventions

JBI-802

LSD1/HDAC6 inhibitor

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or females aged ≥18 years at Screening
• Absolute neutrophil count (ANC) ≥1500 cells/mm3.
• Platelet count ≥100,000 cells/mm3.
• Total bilirubin ≤1.5×ULN. Patients with Gilbert's syndrome may be enrolled with up to 3.0xULN.
• AST and ALT ≤2.5×ULN (unless liver metastases are present then up to 5×ULN is allowed).
• Calculated creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula).
• Prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN if participant is not anticoagulated (Note: If participant is on anticoagulants, the participant must be on a stable dose for at least 2 weeks prior to study entry.
• Must have at least one measurable lesion on CT scan or MRI per RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
• Other criteria may apply

Part 1:

• Participants with a histologically confirmed diagnosis of locally advanced or metastatic solid tumors (except microsatellite stable colorectal cancer and hepatocellular carcinoma) who have no available effective therapeutic options.

Part 2:

• Small cell lung cancer: Participants must have a histologic diagnosis of advanced SCLC not amenable to curative therapy and have received ≤2 prior regimens, which must have included a checkpoint inhibitor and a platinum-based chemotherapy.
• De novo or treatment-emergent NEPC
• Basket of neuroendocrine-derived tumors, excluding SCLC and treatment-induced NEPC. Participants must have unresectable locally advanced or metastatic disease and have no available effective therapeutic options.

Exclusion Criteria

• Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases - defined as metastasis having no evidence of progression or hemorrhage for at least 4 weeks after treatment (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of symptomatic brain metastases for at least 14 days prior to enrollment.
• Severe or unstable medical condition, such as congestive heart failure (New York Heart Association [NYHA] Class III or Class IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (≥Grade 2, according to NCI CTCAE Version 5), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent cardiac illness. Note: Stable chronic atrial fibrillation is allowed.
• Use of strong inhibitors of CYP3A within 14 days or 5 half-lives (whichever is longer) or grapefruit juice or grapefruit containing products within 7 days prior to Cycle 1 Day 1.
• Use of strong inducers of CYP3A within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
• Use of strong inhibitors of cytochrome CYP2D6 within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
• Use of strong inducers of CYP2D6 within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
• History of other previous or concurrent cancer that would interfere with the determination of safety or efficacy assessment
• Surgery (eg, stomach bypass) or medical condition that might significantly affect absorption of medicines
• Other criteria may apply

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jubilant Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Program Manager

Role: STUDY_DIRECTOR

Jubilant Therapeutics Inc.

Locations

Sarah Cannon Research Institute at HealthOne

Denver, Colorado, United States

Site Status: COMPLETED

The Christ Hospital

Cincinnati, Ohio, United States

Site Status: RECRUITING

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Site Status: COMPLETED

NEXT Virginia, LLC

Fairfax, Virginia, United States

Site Status: COMPLETED

Countries

United States

Central Contacts

Chief Scientific Officer

Role: CONTACT

luca.rastelli@jubilanttx.com

(443) 515-9637

Director, Program Management

Role: CONTACT

rajeev.mohan@jubilanttx.com

Other Identifiers

JBI-802-101

Identifier Type: -

Identifier Source: org_study_id